Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?
Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer's disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone detailed assessment including CSF measures, went on to have amyloid PET. The treating neurologist's working diagnosis, and degree of diagnostic certainty, was assessed both before and after the PET. Amyloid PET changed the diagnosis in 7/20 cases. Amyloid PET can provide added diagnostic value, particularly in young-onset, atypical dementias, where CSF results are borderline and diagnostic uncertainty remains.
['Weston|Philip S J|PS|', 'Paterson|Ross W|RW|', 'Dickson|John|J|', 'Barnes|Anna|A|', 'Bomanji|Jamshed B|JB|', 'Kayani|Irfan|I|', 'Lunn|Michael P|MP|', 'Mummery|Catherine J|CJ|', 'Warren|Jason D|JD|', 'Rossor|Martin N|MN|', 'Fox|Nick C|NC|', 'Zetterberg|Henrik|H|', 'Schott|Jonathan M|JM|']
D000368:Aged D016229:Amyloid beta-Peptides D015415:Biomarkers D003704:Dementia D005260:Female D006801:Humans D008297:Male D008875:Middle Aged D010446:Peptide Fragments D049268:Positron-Emission Tomography D016875:tau Proteins
PET cerebrospinal fluid biomarker diagnosis Alzheimer’s disease clinical decision-making